Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy

• Váldodahkkit: Lin Xia (Dahkki), Ruopeng Su (Dahkki), Zhiqiang An (Dahkki), Tong-Ming Fu (Dahkki), Wenxin Luo (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2018-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Human cytomegalovirus (HCMV) causes considerable morbidity and disability in high risk, immunocompromised populations including recipients of solid organ transplants, and fetuses whose immune systems are not yet mature. Vaccines aimed at ameliorating the severity of disease and preventing HCMV infec...